DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This is a Final Office Action.
A corrected interview summary from September 16, 2026, is provided herewith.
Claims 1, 3 and 5-18 are pending and under consideration.
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 103
The rejection of claims 1-18 under AIA 35 U.S.C. 103(a) as being unpatentable over Walter et al. (US 20160096800) in view of Li et al (The Journal of Clinical Investigation, 2018, 128(11), S150-S162), and Jung et al. (International Journal of Molecular Sciences, 2020, 21, 1-26) is withdrawn based on the amendments.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
This a new rejection.
Claims 1, 3 and 5-18 are rejected under AIA 35 U.S.C. 103(a) as being unpatentable over Walter et al. (US 20160096800) in view of Evans et al. (WO 2019193540), Li et al (The Journal of Clinical Investigation, 2018, 128(11), S150-S162), and Jung et al. (International Journal of Molecular Sciences, 2020, 21, 1-26).
The present application claims a method of treating hearing loss comprising administering a compound of formula (I) and, specifically the species shown below:
PNG
media_image1.png
166
283
media_image1.png
Greyscale
PNG
media_image2.png
89
223
media_image2.png
Greyscale
.
Walter et al. teaches the following species:
PNG
media_image3.png
193
500
media_image3.png
Greyscale
,
see page 87, the same species shown above, among others, as a modulator for unfolded protein response (UPR), see abstract.
The cited species in the Walter reference does not have the methyl group on the center phenyl ring but instead has a hydrogen. Since a methyl group is considered a homolog of hydrogen these compounds are considered equivalent. The MPEP 2144.09 states “Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977).
Moreover, Walter teaches methyl and hydrogen as alternatively useable at this position, see the genus teaching on page 1, paragraph [0010] for ring A and page 7, paragraph [0061].
Evans teaches a similar compound or guidepost as an inhibitor of ATF6, which is in the unfolded protein response (UPR) pathway with a methyl group at the same location on the molecule, see page 97, compound 15, which is also provided below:
PNG
media_image4.png
171
466
media_image4.png
Greyscale
.
Thus, a hydrogen and methyl group at this position are alternatively useable.
Walter also does not teach the treatment of hearing loss.
Li et al. teaches the modulation of the UPR has been shown to affect multiple forms of hearing loss, including noise-induced hearing loss (NIHL). Modulating the protein CHOP (transcription factor C/EBP homologous protein) and proteins in its signaling pathway (including PERK and eiF2B) can participate in the pathway that inhibits multiple forms of hearing loss. The link between hearing loss and the UPR has been demonstrated by genetic inhibition of the key UPR pathways. Li further teaches ISRIB can modulate the UPR in cell lines, cochlear hair cells and can prevent hearing loss in mice from noise exposure (permanent threshold shift).
Jung et al. also teaches UPR modulation has been shown to affect hearing loss due to a variety of causes, see Table 1, pages 6-10, and the explanation found on pages 11-14.
Moreover, the present specification teaches that a UPR modulator can treat hearing loss, which is age-related, noise-induced, and genetic, or due to ototoxicity, disease and trauma.
Thus, it would be obvious to a person skilled in the art to use the UPR modulator as taught by Walter et al. to treat hearing loss since Li et al., Summers et al., and Rouse et al., teach UPR modulators treat a hearing loss.
Therefore, claims 1, 3 and 5-18 are rendered obvious.
Claims 1, 3 and 5-18 are rejected under AIA 35 U.S.C. 103(a) as being unpatentable over Evans et al. (WO 2019193540) in view of Walter et al. (US 20160096800), Silverman (The Organic Chemistry of Drug Design and Drug Action, Academic Press. Inc. 1992, 19-23), Li et al (The Journal of Clinical Investigation, 2018, 128(11), S150-S162), and Jung et al. (International Journal of Molecular Sciences, 2020, 21, 1-26).
The present application claims a method of treating hearing loss comprising administering a compound of formula (I) and, specifically the species shown below:
PNG
media_image1.png
166
283
media_image1.png
Greyscale
PNG
media_image2.png
89
223
media_image2.png
Greyscale
Evans et al. teaches the following species:
PNG
media_image4.png
171
466
media_image4.png
Greyscale
,
see page 97, the same species shown above, among others, as an inhibitor of ATF6, which is in the unfolded protein response (UPR) pathway, see Background section on pages 1-3.
The only difference between the claimed and cited species is ring A, pyridinyl versus Applicant’s phenyl, or N versus CH as trivalent atoms in an aromatic ring.
Walter teaches similar compounds as a modulator for unfolded protein response (UPR) where these rings or groups are alternatively useable, see page 87:
PNG
media_image3.png
193
500
media_image3.png
Greyscale
.
Moreover, the substitution of a trivalent N for a trivalent CH is a known bioisosteric replacement. Silverman teaches that “Bioisosterism is a lead modification approach that has been shown to be useful to attenuate toxicity or to modify the activity of a lead, and it may have a significant role in the alteration of metabolism of a lead.” See page 19. Silverman further states, “Bioisosteres are substituents or groups that have chemical or physical similarities, and which produce broadly similar biological properties,” see page 19. Silverman identifies the following atoms as trivalent classical isosteres: –CH=; and –N=. Therefore, the trivalent N atom is a classical isostere of the trivalent CH, see page 19, Table 2.2.
Thus, one having ordinary skill in the art at the time the invention was made would have found it obvious to substitute the N atom in the compound of the Evans patent with a CH atom as found in the Walters publication since Silverman teaches the equivalency of N and CH are classical isosteres. There would have been a reasonable expectation of success, since Silverman discloses that bioisosteres are substituents or groups that have chemical or physical similarities, and which produce broadly similar biological properties. Further, a prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 373, 203 USP 245, 254 (COCPA 1979). In re Papesch, 315 F.2d 381, 137 USPO 43 (CCPA 1963) and In re Dillon, 919 F.2d 688, 16 USPO2d 1997 (Fed. Cir, 1990). See also MPEP § 2144.09.
Evans does not teach the treatment of hearing loss.
Li et al. teaches the modulation of the UPR has been shown to affect multiple forms of hearing loss, including noise-induced hearing loss (NIHL). Modulating the protein CHOP (transcription factor C/EBP homologous protein) and proteins in its signaling pathway (including PERK and eiF2B) can participate in the pathway that inhibits multiple forms of hearing loss. The link between hearing loss and the UPR has been demonstrated by genetic inhibition of the key UPR pathways. Li further teaches ISRIB can modulate the UPR in cell lines, cochlear hair cells and can prevent hearing loss in mice from noise exposure (permanent threshold shift).
Jung et al. also teaches UPR modulation has been shown to affect hearing loss due to a variety of causes, see Table 1, pages 6-10, and the explanation found on pages 11-14.
Moreover, the present specification teaches that a UPR modulator can treat hearing loss, which is age-related, noise-induced, and genetic, or due to ototoxicity, disease and trauma.
Thus, it would be obvious to a person skilled in the art to use the UPR modulator as taught by Walter et al. to treat hearing loss since Li et al., Summers et al., and Rouse et al., teach UPR modulators treat a hearing loss.
Therefore, claims 1, 3 and 5-18 are rendered obvious.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray, can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUSANNA MOORE/Primary Examiner, Art Unit 1624